Background: up to 80% of residents in aged care facilities (ACFs) experience pain, and previous studies have found that older patients with pain are often undertreated. Few studies have been conducted in Australia evaluating the use of analgesic therapy in ACF residents. Objective: to explore the use of analgesics among ACF residents, including independent predictors of analgesic use, evaluate analgesic use against pain management guidelines and identify potential medication management issues. Methods: a retrospective analysis of 7,309 medicines reviews conducted on Australian ACF residents was undertaken. Medication use was compared with published guidelines relating to the management of pain in elderly patients or ACF residents. Multiple variable logistic regression was used to identify independent predictors of analgesic use. Results: nearly 91% of residents were prescribed analgesics. Of those, 2,057 residents were taking regular opioids (28.1%). Only 50% of those taking regular opioids received regular paracetamol at doses of 3-4 g/day. The concurrent use of sedatives was high, with 48.4% of those taking regular opioids also taking an anxiolytic/hypnotic. Conclusion: there is a need to optimise the prescribing and administration of regular paracetamol as a first line and continuing therapy for pain management in ACF residents, to potentially improve pain management and reduce opioid requirements. Furthermore, with the risk of falls and fractures increased by concurrent use of opioids and sedatives, the widespread use of these drugs in a population already at high risk was concerning, indicating a need for better education of health professionals in this area.
Introduction
Pain in the elderly is a common issue, with up to 80% of residents in aged care facilities (ACFs) experiencing persistent pain [1] . Despite persistent pain being recognised as a major cause of disability in elderly patients, significant undertreatment in this population has been reported [2] [3] [4] [5] .
Age-related changes affect how the elderly experience pain, including a reduced production of endogenous analgesic substances and changes in pain perception [6, 7] . Furthermore, there is greater heterogeneity in the way older patients respond to medications, including analgesics [8] . This is partly attributable to pharmacokinetic and pharmacodynamic changes [9] , but also to comorbidities that potentially affect the response to analgesics [10] .
A number of guidelines relating to the management of pain in elderly patients or ACF residents exist. Generally, these recommend regular (by-the-clock) dosing of analgesics for patients with persistent pain [11] , with paracetamol recommended as the first line option [9] (1 g 6 hourly) [11] and continued as a baseline analgesic when more potent agents (e.g. opioids) are added [8, 11] . The use of weak opioids in the management of both cancer pain and chronic pain has been debated, which some suggesting that low dose strong opioids are a more suitable alternative after nonopioid analgesics have failed to adequately manage pain alone [12] . Guidelines also recommend that, due to the risk of side-effects, non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided if possible, or used at the lowest effective dose for the shortest period of time [9, 11] . Potentially, these restrictive recommendations make guidelines difficult to follow in practice, leaving prescribers with relatively few options to treat pain among elderly patients.
Another complication when treating pain in the elderly is the prevalence of comorbidities and high rates of polypharmacy, increasing the risk of adverse drug events. Certain types of pain [13] , as well as some analgesics, have been implicated in increasing the risk of falls [13, 14] . With the consequences of falls and fractures being so significant in the elderly, it is challenging for clinicians to minimise this risk while still adequately controlling pain.
In Australia, few studies have been undertaken to evaluate the use of analgesics in ACF residents [15] [16] [17] . With limited options to manage pain in this group and multiple conflicting treatment priorities, this study aimed to investigate pain management practices in ACFs, identify patient factors that increase the likelihood of analgesic use, and examine any medication management issues.
Methods

Study population
ACFs in Australia provide a range of support from high dependency (nursing home) to low dependency (residential homes). Residents from both high and low dependency care have been included in this review. The Australian Government funds biennial Residential Medication Management Reviews (RMMR) by accredited pharmacists for any Australian residents who live permanently in an ACF, to attempt to reduce the occurrence of drug-related problems. Several different software programmes exist to aid pharmacists with handling data obtained during their review, assessing medications and writing reports; one of which is Medscope™. It is estimated that 20-25% of all reviews conducted in Australia involve use of this software system. The Medscope™ database includes basic demographic details, prescription and over the counter medications (including prescribed dose and directions) and brief medical history, which are entered by the pharmacist conducting the review. De-identified data from all RMMRs recorded in the database between January 2010 and June 2012 were extracted from Medscope™ and were included in the study.
Prescribed therapies
Analgesics evaluated in this study included paracetamol, NSAIDs (including aspirin at doses ≥300 mg/day) and opioids. Opioids were classified as being taken as a regular dose (RD) or not (if taken on an as required basis). Oral Morphine Equivalence per day (MEQ/d) was calculated [18] . Opioids used predominantly as antitussives (dihydrocodeine or pholcodine), or codeine linctus with a direction indicating that its use was for cough or diarrhoea, were not included as analgesics. The following opioids were classified as weak: tramadol, codeine and dextropropoxyphene; with morphine, oxycodone, fentanyl, buprenorphine, methadone and hydromorphone classified as strong opioids. Paracetamol was defined as being optimised if the daily dose was 3-4 g and given by-the-clock. Anxiolytics/hypnotics were defined as benzodiazepines and non-benzodiazepines hypnotics (zopiclone and zolpidem); other sedating agents (antidepressants, antipsychotics and sedating antihistamines) were also recorded.
In ACFs, residents have their medication managed by nursing staff in multidrug blisters, packed by pharmacies. For this reason, prescribed doses for RD medications are likely to reflect medications administered to the patient. However, for 'as required' medications, the dose and frequency administered to the patient is not specified in the database.
Co-morbidities
The Charlson Co-morbidity Index (CCI) [19] score was calculated for each patient. Pain was classified into musculoskeletal pain, which included the following conditions: back pain, joint pain, spondylosis and osteoarthritis; and pain not otherwise specified ( pain NOS), which included the following medical descriptions noted in the medical history: 'pain', 'chronic pain', neuropathic pain/nerve pain/post-herpetic neuralgia, fibromyalgia and headache/migraine. Other chronic medical conditions previously noted to be associated with different patterns of pain or increased usage or risk of problems associated with analgesics ( particularly opioids) were also determined, including a history of substance abuse [20] , depression and/or anxiety [20] , falls [14] , dementia [21] , Parkinson's disease [22] , diabetes [22] , chronic obstructive pulmonary disease (COPD) [23] , stroke [24] , congestive heart failure (CHF) [2] , osteoporosis [25] and fractures [4] .
Statistical analysis
Statistical analysis was performed using SPSS Statistics 20 for Windows (SPSS, Inc., Chicago, IL, USA). Chi-square, MannWhitney U and Wilcoxon Signed Rank tests were undertaken to evaluate differences between patient characteristics and analgesic use. Multiple variable binary logistic regression was subsequently used to analyse the independent associations between non-injectable analgesic use and patient demographics, co-prescribed therapies and co-morbidities. All variables with P-values < 0.1 were assessed for multicollinearity prior to inclusion in the multiple variable binary logistic regression model.
Results
The majority of residents were women (68.7%), with an average age of 84.4 (±9.1) and an average CCI score of 1.9 (±1.5). There were 33 reviews that had no documented medical history and these were removed from the analysis, leaving 7,309 reviews. Of those, 6,634 residents were prescribed analgesic at the time of review; 2,057 residents (28.1%) were prescribed RD opioids (86.5% of opioids were strong opioids; 9.5% weak opioids and 4.0% both strong and weak opioids). Of those residents taking RD opioids, 50.1% were taking optimised paracetamol. There was no significant difference between the CCI score of those prescribed analgesics and those not (P = 0.50). However, there was a small, but statistically significant difference, in the CCI score between those taking RD opioids and those not (1.97 versus 1.87; P = 0.01). Table 1 shows the pattern of all analgesics used in the study population. Non-opioid analgesics only were prescribed to 51.9% residents, with 36.6% prescribed both nonopioid and opioid analgesics. Table 2 shows the proportion of each opioid prescribed; the majority of opioids prescribed to residents were strong opioids (80.6%), with weak opioids accounting for 19.4% of opioids prescribed. The mean dose of RD opioids was 57.8 mg MEQ/d (±79.5 mg) and the median dose of RD opioids was 30 mg MEQ/d. There was no statistical difference between the RD opioid dose of those with a history of falls and those without (P = 0.50).
Anxiolytics/hypnotics were prescribed to 41.5% of the residents, with 43.2 and 48.4% of those taking analgesics and RD opioids, respectively, also prescribed these sedative drugs. There was no statistical difference between the MEQ/ d for those on RD opioids who were taking an anxiolytic/ hypnotic and those not (P = 0.19). Of those patients prescribed anxiolytics/hypnotics, 55% did not have a documented history of insomnia or anxiety/depression. Table 3 shows the likelihood of residents being prescribed analgesics, non-injectable opioids, RD opioids and optimised paracetamol. Opioids were more likely to be prescribed to females, and those with a history of musculoskeletal pain, pain NOS, history of fractures, osteoporosis or taking anxiolytics/hypnotics or other sedating agents. Patients taking opioids or RD opioids were more likely to have a history of cancer; RD opioids and optimised paracetamol were more likely to be taken by patients with a history of CHF. Patients with dementia were less likely to receive optimised paracetamol, opioids or RD opioids.
Discussion
Previous studies have noted low use of analgesics in elderly patients [2] [3] [4] [5] . This study found that the vast majority (90.7%) of residents were prescribed an analgesic (62.8% taking analgesics regularly), which is considerably higher than the level of analgesic use found in a previous Australian study [15] . This increase could be partially attributed to the Australian Pain Society's Guidelines on the management of pain in ACF [11] being released in 2005, increasing awareness of the management of pain in the elderly. Potentially the patients in our study may have also been seen by pharmacists previously for a review in an attempt to improve pain management. Consistent with other studies [2, 4] , we found that paracetamol was the most commonly prescribed analgesic. However, the use of optimised paracetamol was low, only being prescribed to 40% of residents overall and 50% of those patients on RD opioids, which are similar rates to those found in other studies [4] . The use of NSAIDs was low, which is in line with clinical guidelines [9] .
Three major medication issues were identified in the study: (i) low use of optimised paracetamol, particularly in patients who were taking RD opioids; (ii) high use of anxiolytics/ hypnotics in combination with opioids, which substantially increases the risk of falls and fractures; and (iii) potentially suboptimal management of pain in patients with dementia. Although the safety of paracetamol at therapeutic doses has recently been questioned by some [26] , it is generally regarded as the safest option available for elderly patients and is recommended by guidelines [8, 9] as a first line option for pain management. The use of regular paracetamol at an appropriate dose was low, particularly in patients taking RD opioids. This is consistent with a recent Australian study [17] evaluating oxycodone use in a similar population, which found that only 41% of residents of ACFs had had a trial of a non-opioid analgesic prior to commencing oxycodone. These findings suggest that the use of paracetamol in chronic pain needs to be given a Equals more than 100% as the average number of opioids used per resident (using opioids) was 1.9.
prominence in clinical guidelines, particularly as a means to minimise use of opioids, their associated side-effects and improve pain management. There may be a place for regulatory bodies, which approve and monitor long-term opioid therapy, to require maximum tolerated doses of paracetamol be used before the addition, or dose escalation, of opioids. The second issue was the use of anxiolytics/hypnotics in combination with opioids, both of which increase the risk of falls and fractures [14, 27, 28] . The combination is not recommended, particularly in the elderly, due to falls risk [29] . It appears that warnings about the danger of combining sedating agents, such as anxiolytics/hypnotics with opioids, are not being heeded. There is a need to increase the education of health professionals about such combinations in an attempt to minimise their use, while still addressing the requirement for adequate pain relief.
The third issue identified was the low use of analgesics in patients with a history of dementia, which has been noted previously [21] . Potentially, this may indicate judicious use of medications, in that these patients have high potential to develop adverse events with opioids [30] . However, it is unlikely that these patients experience less pain than their counterparts without dementia [21] , and the low level of optimised paracetamol and opioid use in this group, indicates that patients with dementia are likely to have suboptimal pain management. Increased emphasis of regularly dosed analgesics, particularly paracetamol, in patients with dementia should be encouraged if pain is suspected. This is particularly important in patients with a history of dementia, as often these patients are unable to request or adequately communicate pain and thus regular dosing of analgesics is essential to assist in managing the patient's pain.
The pattern of opioid use in published studies is highly variable. Nearly 40% of the residents reviewed in our study were documented as receiving opioids, which is consistent with some other studies [4, 16] , but not all [22] . Of those taking opioids, 72.4% were taking opioids regularly, which is higher than previously reported [15] . There was also greater use of strong opioids than previously noted [2] , accounting for 80.6% of opioids prescribed. However, the use of weak opioids was still relatively high, potentially indicating prescriber's concerns over the use of strong opioids in this patient group or perceived efficacy. As the trial evidence to support the use of weak opioids is difficult to extrapolate to clinical practice [12] this use may be justified and suitable in these patients. Not surprisingly, musculoskeletal pain, pain NOS, fractures and osteoporosis were the most likely independent factors associated with analgesic use. Residents with a history of CHF were more likely to use RD opioids and optimised paracetamol, in contrast to another study [2] that found ACF residents were less likely to receive opioids if they had a history of CHF. Potentially, this increased use of opioids reflects the avoidance of NSAIDs in patients with heart failure as well as increased acceptance of the use of opioids for persistent pain in elderly patients.
There are some limitations associated with this data set. The clinical indications for analgesic use, cause of pain or satisfaction with pain management were not able to be determined from the data. In addition, medications were listed with their prescribed directions rather than administered dose, which is particularly relevant to medications given on an 'as required' basis, and therefore we may have underestimated the extent of use of these medications. However, as the vast majority of ACFs use pharmacist-prepared medication packs administered by nursing staff, the prescribed dosages for RD medications are likely to represent the actual usage. There is the potential that pharmacists may be more likely to use decision support software where patients are more clinically complicated. However, chronic pain is difficult to manage and these patients tend to have multiple comorbidities, for this reason it is expected that the results from this study are consistent with analgesic use in Australian ACF. Despite these limitations, these data still have some significant strengths, including the large patient population throughout Australia, no recall bias, and the inclusion of both prescription and over the counter medication. In addition, this sample appeared to be broadly representative of Australian ACF residents, which is not unsurprising noting that the vast majority of residents in ACFs undergo a medicines review
Conclusion
Three medication management issues were identified: low rates of optimised paracetamol use, particularly in patients taking regular opioids; high concurrent use of anxiolytics/ hypnotics with opioids and potentially inadequate pain management in patients with dementia. The risk of falls and fractures with opioids is a strong reason to encourage the prescribing and administration of regular paracetamol at a dose of 3-4 g/day, before the addition or up-titration of opioids, particularly when the patient is also taking sedating agents. It is clear there is a need for increased education of ACF staff and medical practitioners in an attempt to minimise potentially risky combinations of sedating agents. There is also a need to emphasise that optimised paracetamol should be used as a baseline and ongoing analgesic in the management of pain. In addition, regulatory bodies could have a role to play in requiring paracetamol to be prescribed at an optimised dose as a baseline analgesic before approval for long-term opioids is granted.
Key points
• The use of regular paracetamol in patients taking regular opioids was low.
• Anxiolytics and hypnotics use was high in patients taking opioids regularly.
• Nearly 91% of residents received analgesics.
